Certified Advisory Corp’s AstraZeneca AZN Stock Holding History

Certified Advisory Corp’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1	Closed	–	–	247
2021 Q1	$0	Buy	+1	New	+$101	﹤0.01%	774

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Certified Advisory Corp's AZN Position: Q2 2021 in Review

Certified Advisory Corp sold out of AstraZeneca (AZN) in Q2 2021, closing a stake of 1 share.

Certified Advisory Corp first reported a position in AZN in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 768 funds tracked by Wall St. Rank hold AZN as of Q2 2021.

Certified Advisory Corp reported no remaining AstraZeneca position as of Q2 2021 after selling out during the quarter.
Certified Advisory Corp sold 1 AstraZeneca share in Q2 2021.
Certified Advisory Corp first reported a position in AstraZeneca in Q1 2021 and held it in 1 quarter.
Certified Advisory Corp's AstraZeneca position peaked at $0 in Q1 2021.
768 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2021.

Based on Certified Advisory Corp's 13F filing for Q2 2021, filed 16 Aug 2021.